The role of PD-1 signaling in health and immune-related diseases

The role of PD-1 signaling in health and immune-related diseases

Programmed cell death 1 receptor (PD-1) and its ligands constitute an inhibitory pathway to mediate the mechanism of immune tolerance and provide immune homeostasis. Significantly, the binding partners of PD-1 and its associated ligands are diverse, which facilitates immunosuppression in cooperation...

Full description

Bibliographic Details
Main Authors:	Ru-Yue Chen, Yun Zhu, Yun-Yan Shen, Qin-Ying Xu, Han-Yun Tang, Ning-Xun Cui, Lu Jiang, Xiao-Mei Dai, Wei-Qing Chen, Qiang Lin, Xiao-Zhong Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Immunology
Subjects:	programmed cell death 1 receptor immune checkpoint proteins immune tolerance tumor microenvironment autoimmune diseases immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1163633/full

Similar Items

The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
by: José M. Carballido, et al.
Published: (2020-03-01)

Tumor microenvironment and immunotherapy of oral cancer
by: Chang Liu, et al.
Published: (2022-10-01)

CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas
by: Depei Li, et al.
Published: (2021-03-01)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
by: Ruiwen Ruan, et al.
Published: (2023-03-01)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
by: Zihan Zhao, et al.
Published: (2023-03-01)

A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
by: Xiaohan Zhou, et al.
Published: (2021-07-01)

Immunogenic cell death mediation patterns reveal novel paradigm for characterizing the immune microenvironment and immunotherapeutic responses in bladder cancer
by: Jialei Fu, et al.
Published: (2022-10-01)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
by: Chao Cheng, et al.
Published: (2022-09-01)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
by: Marcella Willemsen, et al.
Published: (2020-11-01)

Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
by: Kamila Wojas-Krawczyk, et al.
Published: (2021-08-01)

An Immunological Glance on Pancreatic Ductal Adenocarcinoma
by: Michael Karl Melzer, et al.
Published: (2020-05-01)

GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis
by: Liangliang Wang, et al.
Published: (2023-02-01)

Actors on the Scene: Immune Cells in the Myeloma Niche
by: Patrizia Leone, et al.
Published: (2020-10-01)

Grand Challenge « Tumor immunology, towards a success story ? »
by: Catherine eSautès-Fridman
Published: (2015-02-01)

Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
by: Adam Mor, et al.
Published: (2022-01-01)

Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
by: Nicolas Huyghe, et al.
Published: (2022-04-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01)

Immune Checkpoints in Solid Organ Transplantation
by: Arnaud Del Bello, et al.
Published: (2023-10-01)

Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer
by: Li-Hong He, et al.
Published: (2023-04-01)

Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment
by: So Young Yoo, et al.
Published: (2020-06-01)

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
by: Junyu Long, et al.
Published: (2022-02-01)

Research progress of immunotherapy against anaplastic thyroid cancer
by: Jiaqian Chen, et al.
Published: (2024-03-01)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01)

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade
by: Cheng Xu, et al.
Published: (2023-04-01)

Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures
by: Xiao Han, et al.
Published: (2022-01-01)

Editorial: Progress of programmed cell death in antitumor immunity
by: Fangfang Yan, et al.
Published: (2023-06-01)

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
by: Xiang Chen, et al.
Published: (2024-02-01)

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience
by: Juřica Jan, et al.
Published: (2022-06-01)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
by: Yu Yuan, et al.
Published: (2021-02-01)

Editorial: Overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine
by: Aimin Jiang, et al.
Published: (2024-04-01)

Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
by: Pratibha Pandey, et al.
Published: (2023-01-01)

A brief glimpse of a tangled web in a small world: Tumor microenvironment
by: Iman M. Talaat, et al.
Published: (2022-08-01)

Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges
by: Muhammad Zaeem Noman, et al.
Published: (2019-09-01)

Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies
by: I-Tsu Chyuan, et al.
Published: (2021-03-01)

Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinomaKey points
by: Xinjun Lu, et al.
Published: (2023-07-01)

Tumor immunotherapy: Mechanisms and clinical applications
by: Cheng Nong, et al.
Published: (2022-06-01)

Heterogeneity of the tumor immune microenvironment and its clinical relevance
by: Qingzhu Jia, et al.
Published: (2022-04-01)

Immunotherapy in cholangiocarcinoma: From concept to clinical trials
by: Wen-Yan Yao, et al.
Published: (2021-06-01)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
by: Qingxu Liu, et al.
Published: (2023-11-01)